Large cell neuroendocrine lung cancer（LCNEC） is the rare subtype of nonsmall cell lung cancer. Because of its low incidence rate and the special biological behaviour, it is hard to define in pathology. And we also know little about its epidemiological feature and the purposeful therapy view of LCNEC, and the therapeutic effect is unsatisfactory. This article will review and introduce the advance of research, clinical diagnosis and therapeutic of the LCNEC.
Objective To summary the pathological classification， clinical manifestations， diagnosis， and treatments of gastrointestinal neuroendocrine tumors （GE-NETs）. Methods Domestic and international literatures were collected to summary the status of clinical researches and treatments of GE-NETs. Results GE-NETs derived from enterochromaffin cells throughout the gut which had the function of amine precursor uptake decarboxylase （APUD）. These tumors secreted discrete bioactive substances and produced characteristic immunohistochemical patterns， making patients to manifest endocrine syndrome. But there were no unified standards on the diagnosis， grade， TNM classification， and prognosis of GE-NETs. Early diagnosis rate of GE-NETs was low， and most of tumors were asymptomatic and detected at late stage， with a tendency to metastasize to the liver. Imaging examation was important in early diagnosis of GE-NETs. Surgery was the traditional first-line therapy and the only possible curative approach. Somatostatin analogues， such as long-term-release （LAR） octreotide， could relieve the hormonal symptoms， slow down the tumor growth， and had shown synergistic antiproliferative activity in combination with biological agent everolimus. Conclusions The lack of standardized classification and an incomplete understanding of this disease are some of the impediments to the progress of treatment. Individualized comprehensive therapy is the aim of the future treatment.
Objective To summarize the application and advancement of liver transplantation for hepatic metastasis from neuroendocrine tumor. Methods Domestic and overseas publications on the study of liver transplantation for hepatic metastasis from neuroendocrine tumor in recent years were collected and reviewed. Results Liver transplantation can offer good relief of symptoms, long disease-free intervals, and potential cure in individual patients with hepatic metastatic tumor. Important selection criteria are well-differentiated tumors and a low proliferation rate (Ki67＜10%). Conclusion In carefully selected patients with metastatic neuroendocrine tumors, liver transplantation is an appropriate option.
目的总结直肠神经内分泌肿瘤（RNEN）的临床诊断和治疗方法。 方法回顾性分析2009年1月至2013年12月期间南京中医药大学附属医院（江苏省中医院）收治的16例RNEN患者的临床资料。 结果16例患者均顺利完成手术，手术时间30～120 min，平均50 min；术中出血量10～80 mL，平均55 mL；均无手术死亡，术中均未见严重并发症发生。术后住院时间10～35 d，平均17 d。手术创面均一期愈合，均顺利出院。术后所有患者均获访，随访时间为2个月～5年，中位随访时间为20个月。随访期间所有患者均未见复发或转移，无死亡病例。 结论RNEN发病隐匿，具有恶性潜能，且常无特异性临床表现，故应加深对该病的认识，及时对就诊患者进行全面检查，做到早发现、早诊断及早治疗，且治疗后应对患者进行严密随访。
ObjectiveTo evaluate the effect of surgical management of neuroendocrine liver metastasis. MethodsLiteratures about the surgical management of neuroendocrine liver metastasis were collected and reviewed. ResultsEffect of surgical treatment for neuroendocrine liver metastasis was confirmed, but the molecular mechanism of tumor formation was more complex, and the recurrence rate of surgery was too high, so a large number of new treatment methods had been developed and used clinically, and had achieved good results. These treatments included external beam radiotherapy, internal radiotherapy, liver transplantation, and targeted therapies. ConclusionComprehensive surgical management will be the direction of surgical management of neuroendocrine liver metastasis.
目的探讨胰腺血管活性肠肽瘤（VIPoma）的临床、实验室和影像学特点，以及诊断方法和治疗手段。 方法报道1例胰腺VIPoma，同时检索国内文献得到49例胰腺VIPoma患者临床资料，并对此50例病例进行分析。 结果分泌性腹泻、低血钾和代谢性酸中毒是胰腺VIPoma的主要临床表现，血浆血管活性肠肽（VIP）水平增高具有诊断价值。经手术治疗，腹泻症状可减轻或消失；对于远处转移患者，生长抑素、化疗、干扰素等治疗均有效。 结论VIPoma早期诊断困难，确诊依赖于典型临床症状、血浆VIP水平、影像学检查以及免疫组化检查。手术切除可改善预后，生长抑素等治疗可缓解症状，发生转移者也应积极治疗。